Skip to main content
VCbacked
Log inGet Started

Pin Therapeutics

Seongnam, South Korea

Pin Therapeutics is a pharmaceutical startup focusing on advanced protein degradation therapeutics.

$13.6M raised
Dec 2024
Series C
BiotechnologyManufacturingPharmaceutical

Top Investors

KOREA INVESTMENT & SECURITIESKorea Investment PartnersDaewoong PharmaceuticalYuanta InvestmentKorea Development Bank

Founder Contacts

19,000+ verified contacts
Get Instant Access

Emails, phones & LinkedIn profiles

Frequently Asked Questions about Pin Therapeutics

How much funding has Pin Therapeutics raised?
Pin Therapeutics has raised $13.6M in total funding. The most recent round was Series C. The last funding was announced in December 2024.
Who are Pin Therapeutics's investors?
Pin Therapeutics's investors include KOREA INVESTMENT & SECURITIES, Korea Investment Partners, Daewoong Pharmaceutical, Yuanta Investment, Korea Development Bank.
Where is Pin Therapeutics headquartered?
Pin Therapeutics is headquartered in Seongnam, South Korea.
What does Pin Therapeutics do?
Pin Therapeutics is a pharmaceutical startup focusing on advanced protein degradation therapeutics.
What stage is Pin Therapeutics at?
Pin Therapeutics is at the Series C stage.
Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .

MLA
"Pin Therapeutics — Funding & Investors." VCBacked, December 27, 2024, https://www.vcbacked.co/company/pin-therapeutics. Accessed June 4, 2026.
APA
VCBacked. (2024). Pin Therapeutics — Funding & Investors. Retrieved June 4, 2026, from https://www.vcbacked.co/company/pin-therapeutics
Wikipedia (cite web)
{{cite web |title=Pin Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/pin-therapeutics |website=VCBacked |access-date=June 4, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated .

Similar Companies in Biotechnology

View all
Virtuoso Surgical
Nashville
Pharvaris
Zug
Odyssey Therapeutics
Boston$213.0M
Tempus
Chicago
Anagram Therapeutics
Boston
Prenetics
Hong Kong